

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**



Europäisches Patentamt
European Patent Office
Office européen des brevets

⑪ Publication number:

0 128 655

B1

⑫

EUROPEAN PATENT SPECIFICATION

- ⑯ Date of publication of patent specification: **23.01.91** ⑮ Int. Cl.⁵: **A 61 K 6/02**
⑯ Application number: **84302979.4**
⑯ Date of filing: **03.05.84**

④ Benzoin antimicrobial dental varnishes.

EP 0 128 655 B1

⑩ Priority: 11.05.83 US 493755	⑦ Proprietor: University of Toronto Innovations Foundation 203 College Street Toronto, Ontario M5T 1P9 (CA)								
⑯ Date of publication of application: 19.12.84 Bulletin 84/51	⑦ Inventor: Sandham, H. James 63 Thorny Brae Drive Thornhill Ontario, L3T 3G5 (CA) Inventor: Balanyk, Thomas E. Apt. 406 1101 Bay Street Toronto Ontario, M5S 2W8 (CA)								
⑯ Publication of the grant of the patent: 23.01.91 Bulletin 91/04	⑦ Representative: Carter, Gerald et al Arthur R. Davies & Co. 27 Imperial Square Cheltenham, Gloucestershire GL50 1RQ (GB)								
⑯ Designated Contracting States: AT BE CH DE FR GB IT LI LU NL SE									
⑯ References cited: <table><tr><td>EP-A-0 022 662</td><td>FR-A-2 486 392</td></tr><tr><td>DE-A-2 514 435</td><td>US-A-3 431 208</td></tr><tr><td>DE-A-2 722 187</td><td>US-A-4 322 308</td></tr><tr><td>FR-A-2 315 948</td><td>US-A-4 348 378</td></tr></table>	EP-A-0 022 662	FR-A-2 486 392	DE-A-2 514 435	US-A-3 431 208	DE-A-2 722 187	US-A-4 322 308	FR-A-2 315 948	US-A-4 348 378	
EP-A-0 022 662	FR-A-2 486 392								
DE-A-2 514 435	US-A-3 431 208								
DE-A-2 722 187	US-A-4 322 308								
FR-A-2 315 948	US-A-4 348 378								

CHEMICAL ABSTRACTS, vol. 97, no. 8, August 1982, page 326, no. 60957e, Columbus, Ohio, US; M. FRIEDMAN et al.: "New sustained release dosage form of chlorhexidine for dental use. I. Development and kinetics of release"

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European patent convention).

Description

The present invention relates to compositions for treatment and prevention of oral infections as defined in the patent Claims.

5 Evidence is accumulating which indicates that both dental caries and periodontal disease may result from infection by specific components of the oral microflora. Elimination of these infections should therefore contribute to treatment and prevention of these disorders.

10 It is known to apply antiseptics topically to teeth, gums etc., as mouthwashes and in gels. Systemic administration of antibiotics is sometimes prescribed for treatment of periodontal disease. While both such methods are effective in reducing oral bacterial counts, the active ingredients seldom remain at the site of 15 infection in effective concentration for a time long enough for fully effective treatment. Topically applied liquid antiseptics such as mouthwashes are easily washed from the infection site by salivation and routine mastication.

15 A properly effective, convenient and patient-acceptable means for effecting treatment of dental infections, such as dental caries caused by *Strep. mutans* infections, has not heretofore been developed. Such a means needs to be effective to contact the site of infection with the antimicrobial treating agent over an extended period of time, for example several days. Moreover, it should be capable of effecting treatment without the over-frequent or continuous adjustments, modifications, inspections and monitorings requiring professional attention. It must of course resist premature removal from the infected site as a 20 result of normal salivation, mastication and intake of food and beverage. Finally, but equally importantly, it must be acceptable to the patient, in terms of its taste, external appearance, texture, effect on oral sensitivities, odour, and freedom from interference with normal oral functions.

25 It is also known to use a composition consisting of compound benzoin tincture binder, benzocaine and cetylpyridium chloride with other ingredients, for oral topical application for treatment of canker sores (Blistex Incorporated, "Kank-A"). Such a composition is not, however, suitable for application to teeth to treat or prevent dental caries. Firstly, the formulation contains ingredients which impart an unpleasant, bitter taste thereto, so that it is not acceptable for use in applications where it will be retained in the oral cavity for extended periods of time. Secondly, it imparts discoloration to teeth when applied thereto. Thirdly, it contains toxic ingredients.

30 In one aspect of the present invention, a composition suitable for dental use and effective in combatting growth of disease causing bacteria is provided, the composition comprising at least one dentally acceptable antimicrobial agent, and a dentally and biologically acceptable binder material. The composition as a whole can be adhered to the site of dental infection. The binder material is capable of permitting effective communication of said antimicrobial agent with the infection site when the 35 composition is applied thereto, over an extended period of time, to effect treatment. The residue of the composition after treatment is readily removed at will.

Another aspect of the invention provides a process of treating microbial infections on oral structures such as teeth and gingiva, which comprises painting the infected site with a dental varnish comprising the above composition.

40 A specific preferred binder material is benzoin gum either Sumatra or Siam benzoin, or fractions or recombined fraction thereof (hereinafter referred to as benzoin for brevity), which is capable of adherence to the tissues and enamel of the gingiva and teeth respectively. The benzoin is soluble in ethanol, which constitutes a suitable solvent to make the varnish composition, and is also compatible with several suitable antimicrobial drugs. After application to the infected site, a composition formed from the benzoin, ethanol 45 and antimicrobial agent dries to form a solid, permitting a sustained release of the active antimicrobial ingredient over an extended period of time. Repeated applications for compositions of the present invention are not required on a frequent basis, for effective treatment. It has been found that the antimicrobial agent is effectively maintained at the infection site for at least four days owing to the presence of the benzoin film. The composition can be removed at will, by application of the appropriate solvent, normally ethanol, to the solid or by other standard oral hygiene techniques.

Preferred compositions according to the present invention include a plurality of antimicrobial agents.

A wide variety of dentally acceptable antimicrobial agents can be used in compositions according to the invention, choice among which is determined largely on the basis of the infection which it is required to combat and safety to the patient. Erythromycin and chlorhexidine are examples of suitable preferred agents for combatting common oral bacterial infections.

55 Chlorhexidine is preferably used in the form of an orally acceptable salt thereof, e.g. acetate, hydrochloride or gluconate. Most preferred among chlorhexidine salts is chlorhexidine acetate on account of its appropriate solubility in water and in the preferred solvent ethanol, to provide good rate of release from the film.

60 The relative proportions of binder, antimicrobial agents and solvent in the preferred composition can vary widely. The lower solvent limit is fixed only by the maximum solubility of the other ingredients therein. The ratio of antimicrobial agent to solvent can be anywhere from 0.001% w/v up to a saturated solution thereof, e.g. 20%. The ratio of antimicrobial agent to binder is suitably in the range 10:1 to 1:10 by weight, preferably 5:1 to 1:5, and most preferably 2:1 to 1:2. Precise preferred ratio depends to some extent on the rate of release of the antimicrobial agent from the film. It is preferred to subject the site of

EP 0 128 655 B1

infection initially to relatively large amounts of antimicrobial agent, to reduce the chance of formation of antimicrobial resistance in the infection.

Compositions according to the present invention are best formulated from only three essential ingredients, namely the benzoin binder, the ethanol solvent, and the antimicrobial agent or agents. Such a composition contains only orally acceptable, nontoxic ingredients. It contains no ingredients likely to have the effect of discoloring the dental site to which it is applied. With choice of the most appropriate antimicrobial agents, the hardened film contains no ingredients imparting thereto an unacceptable taste or texture, rendering it unpleasant to the user. It is suitably and conveniently applied by painting onto the site of infection. It adheres strongly to the teeth or gums, and penetrates effectively into all fissures and pits on the tooth surface. After application to the teeth, the composition dries in a relatively short period, e.g. about 3—6 minutes to yield a strongly adherent, clear or tooth-colored film which is effectively invisible whilst in place. It is strong enough to remain on the teeth for an extended period of time, at least four days, and will resist the forces commonly applied during mastication. Whilst the film is in place, of course, the user must refrain from application thereto, of the solvent ethanol as part of the user's drink intake, but the film can nevertheless be removed as and when required, at will, by simple application thereto of ethanol solvent and employment of standard oral hygiene procedures. Whilst in place, the film releases the antimicrobial agent or agents contained therein at a slow, relatively constant rate, and in concentration sufficient effectively to combat the target bacteria over a period of several days. Finally, the solvent used, namely ethanol, is compatible with restorations present in the teeth as well as original tooth enamel and does not dissolve or soften them. If desired, the composition may additionally include small amounts of additional ingredients such as flavorants or flavor maskers texturizers or other tooth treating aids such as fluorides.

In addition to application to teeth, or gingiva by painting thereon as a liquid, dryable varnish, one can also apply compositions of the invention as pastes, e.g. in a toothpaste formulation, as a liquid mouthwash, as a chewable tablet or the like, as long as an adherent film of binder and antimicrobial agent is applied in a semi-permanent manner to the site of infection, e.g., at least overnight.

In the accompanying drawings:

Figures 1, 2 and 3 are graphical representations of the results of experiments reported in Example 4. The invention is further described in the following specific examples:

30 Example 1

Varnish formulation

A formulation according to the invention was made by dissolving 1 gm chlorhexidine acetate in 10 ml of tincture of benzoin, which consisted of a 10% w/v solution of Sumatra benzoin in 95% ethanol, (hereinafter referred to as "Chlorzoin"** formulation). A similar formulation was prepared using erythromycin in place of chlorhexidine (to form an "Erythrozoin"** formulation). These liquid formulations were then used as varnishes, to paint and coat oral structures for a temporary period, as described in the subsequent examples.

Example 2

40 Extracted molars, with clear fissures and containing neither visible caries nor amalgams, were provided. The apical foramen of each tooth was sealed with methyl-2-cyanoacrylate and then the teeth were dried for 24 hours at 22°C. The teeth were then placed in 95% ethanol for 24 hours and dried for four hours at 37°C in covered sterile petri dishes.

Each molar was placed in a tube containing a 20 ml solution of Todd Hewitt broth (THB) and 5% sucrose. Nine tubes were inoculated with 0.1 ml of JC2 strain of *S. mutans* (10^8 /ml in tryptic soy) and another nine molar-containing tubes were inoculated with 0.1 ml of a mixture of *S. mutans* (comprised of E-49, BHT, JC2, PS-14, PS-72, 01H1, 6715, PK1, LM7 and ATCC 10499) of varying concentrations.

The molar and broth-containing tubes were incubated for 72 hours in a 90% N₂, 10% CO₂ atmosphere in standard incubating jars at 37° whereafter the teeth were removed and aseptically transferred to covered sterile petri dishes where they were dried for 2 hours in a warm room (37°).

Nine teeth grown in broth containing only the JC2 strain were painted with 0.1 ml of different varnishes prepared according to Example 1. The first group of three was painted with tincture of benzoin. The second group was painted with Chlorzoin. Erythrozoin was painted on the teeth forming group three.

A similar test was performed on nine teeth incubated with the multi-strain inoculated tubes.

55 The painting was performed with *Fluor-Protector* (Trade Mark) disposable brushes manufactured by Ivoclar-Vivadent. The brushes were gas sterilized before use.

After application of the varnish, the coated teeth were dried on covered sterile petri dishes for 30 minutes at 37°C. All teeth were then placed in 100 ml THB (5% sucrose) solution for 24 hours at 37°C under 90% N₂ and 10% CO₂ atmosphere.

60 The varnishes were then removed with rotating bristle brushes in a slow speed dental handpiece.

To analyze bacterial growth, each tooth was placed in 100 ml of Shklair's medium) at 37°C for 14 days (90% N₂ and 10% CO₂ added). The results are shown in Table I. Bacterial growth is indicated by a change of

65 * trade mark

EP 0 128 655 B1

medium colour from purple to yellow, indicated by "+" in the table below which summarized the results of the procedure supra.

TABLE I

5

	Varnish+JC2				Varnish+mixture			
	Tooth	Benzoin	CZ	EZ	Tooth	BZ	CZ	EZ
10	1	+			10	+		
	2	+			11	+		
15	3	+			12	+		
	4		-		13		-	
20	5		-		14		-	
	6		-		15		-	
25	7		-		16		-	
	8		-		17		-	
30	9		-		18		-	

"+" indicates a color change, and

"-" indicates no color change, after fourteen days.

Table 1 indicates the efficacy of the Chlorzoin and Erythrozoin varnishes in inhibiting growth of *S. mutans* strains *in vitro*.

35 Example 3

In vivo testing of tincture of benzoin and of chlorzoin

An *in vivo* trial was undertaken using tincture of benzoin, both with and without chlorhexidine, as described in Example 1 in the mouth of one of the investigators. The handling and other properties of the preparations were found to be as satisfactory *in vitro* properties. The film formed on the teeth *in vivo* closely resembled that formed *in vitro*. Additionally, the taste of the tincture of benzoin, although balsamic, was not objectionable to the patient. However, when chlorzoin was applied, its taste was objectionable. The taste became acceptable, however, when the teeth were first isolated from one another and dried using cotton roll prior to application of the chlorzoin. The cotton rolls were left in place until after the chlorzoin had hardened (a few minutes).

45

Example 4

Kinetics of release of chlorhexidine from films of "chlorzoin"

The purpose of using varnish as a vehicle for delivering chlorhexidine was to release low levels of chlorhexidine slowly over a period of days in the vicinity of the tooth surface, the only site of *S. mutans* colonization in the mouth.

50 As an aid for predicting the rate of release of chlorhexidine from chlorzoin in the oral cavity, *in vitro* experiments in which solidified films of chlorzoin, of standardized weight (10 mg chlorhexidine and 10 mg of benzoin) and shape, were utilized. The lens-shaped films were prepared by pipetting 0.1 ml of chlorzoin into standardized moulds, and permitting them to dry in the air. The films were then placed in 10 ml of Tris buffer for 15 days. The buffer solutions were constantly agitated and were completely replaced after 6, 12, and 24 hours and daily thereafter.

55 The removed buffer solutions were then assessed for their chlorhexidine content by three methods that were, in preliminary experiments, found to provide reproducible assessments of chlorhexidine concentration. The methods were (i) UV absorption at 256 m μ , (ii) serial two-fold microdilution (Little *et al.*, 1979), and (iii) paper disc-agar diffusion (Barry, 1981). The last two methods are biological assays, utilising antimicrobial effectiveness to estimate chlorhexidine concentration.

60 The results are presented graphically in appended Figs. 1, 2 and 3, derived from triplicate test samples. They show chlorhexidine release for each time interval from 0.02 g of dried chlorzoin film. Following a slow initial release of chlorhexidine for the first 12 hours, there was an almost 10-fold greater release during the second 12 hour period. However, by the end of the third day, chlorhexidine release had decreased to

EP 0 128 655 B1

approximately 0.1 mg per sample per day. Thereafter, it maintained an almost constant rate of release until approximately the 11th day, when the release rate began to fall off to zero by 14 days.

From these results it may be concluded that chlorzoin is capable of releasing chlorhexidine at a low rate over a period of several days, consistent with its use for eliminating *S. mutans* from the human oral cavity. The concentration of chlorhexidine attained in each sample of buffer solution during the period of slow release (approximately days 3 to 11) was approximately 10 µg/ml, a concentration which is known to be bactericidal *in vitro* for *S. mutans*. Thus, the concentration of chlorhexidine released during the slow release period seems potentially adequate to kill *S. mutans* in the immediate vicinity of the teeth.

The above data can also be used to provide a rough estimate of the maximum dose to a patient over a 24 hour period. The amount of chlorzoin required to coat the teeth of an adult subject with a complete natural dentition was found to be approximately 1.5 ml, approximately 15 times greater than that in each sample in these *in vitro* experiments. The results reported here (Figs. 1, 2 and 3) indicate that approximately 1.2 mg of chlorhexidine was released *in vitro* over the first 24 hours, the period of maximum release. If the release rate were assumed to be similar in the human mouth, a human might be expected to ingest a maximum of approximately 18 mg of chlorhexidine (1.2 mg × 15) over a 24 hour period. This amount is well below that generally recognized as safe in humans.

An important feature of the present invention is that the compositions, when applied to teeth, are not readily visible to the outside observer. The films are colorless, clear or translucent, or the same essential color as the teeth themselves. They thus are acceptable both to the dental profession and the user, as an unobtrusive and convenient aid to dental care, which will not risk causing discoloration of the teeth afterwards. Moreover, they are easily formulated so as to be quite acceptable as to taste.

Claims

- 25 1. A dental varnish composition suitable for painting onto teeth to combat oral infection, said composition consisting essentially of:
 - an orally acceptable liquid vehicle;
 - benzoin;
 - and at least one dentally acceptable antimicrobial agent which is compatible with the liquid vehicle and
- 30 the benzoin;
 - said composition being capable of drying to form a solid transparent, translucent or tooth coloured coating on teeth to which it is applied and releasing said at least one antimicrobial agent over a sustained period of time into contact with infected sites on said teeth.
 2. The composition of Claim 1 wherein the liquid vehicle is ethanol.
 - 35 3. The composition of Claim 1 wherein the weight ratio of benzoin to dentally acceptable antimicrobial agent is in the approximate range of 10:1 to 1:10.
 4. The composition of Claim 1 including a plurality of dentally acceptable antimicrobial agents.
 5. The composition of Claim 4 wherein the antimicrobial agent is selected from erythromycin, chlorhexidine, salts thereof and mixtures thereof.
 - 40 6. The composition of Claim 5 wherein the antimicrobial agent is chlorhexidine acetate.

Patentansprüche

1. Zahnlackzusammensetzung, mit der die Zähne anstreichbar sind, um eine orale Infektion zu bekämpfen, wobei die Zusammensetzung im wesentlichen besteht aus:
 - einem oral verträglichen, flüssigen Vehikel;
 - Benzoin; und
 - wenigstens einem dental verträglichen, antimikrobiellen Mittel, das mit dem flüssigen Vehikel und dem Benzoin kompatibel ist;
- 45 50 wobei die Zusammensetzung in der Lage ist zu trocknen, um einen festen, transparenten, lichtdurchlässigen oder zahnfarbenen Überzug auf den Zähnen zu bilden, auf die sie aufgetragen wird, und das wenigstens eine antimikrobielle Mittel über einer ausgedehnten Zeitspanne in Kontakt mit infizierten Stellen auf den Zähnen freizusetzen.
2. Zusammensetzung nach Anspruch 1, wobei das flüssige Vehikel Ethanol ist.
- 55 3. Zusammensetzung nach Anspruch 1, wobei das Gewichtsverhältnis von Benzoin zu dental verträglichem, antimikrobiellem Mittel in dem ungefähren Bereich von 10:1 bis 1:10 liegt.
4. Zusammensetzung nach Anspruch 1, beinhaltend eine Vielzahl von dental verträglichen, antimikrobiellen Mitteln.
5. Zusammensetzung nach Anspruch 4, wobei das antimikrobielle Mittel unter Erythromycin,
- 50 60 Chl rhexidin, Salzen derselben und Gemischen derselben ausgewählt wird.
6. Zusammensetzung nach Anspruch 5, wobei das antimikrobielle Mittel Chlorhexidinacetat ist.

EP 0 128 655 B1

Revendications

1. Compositi n de vernis dentaire destinée au badigeonnage des dents pour combattre l'infection buccale, cette composition se composant essentiellement:
 - 5 d'un véhicule liquide acceptable par voie orale,
 de benzoïne,
 et d'au moins un agent antimicrobien acceptable par voie orale, qui est compatible avec le véhicule liquide et la benzoïne,
 ladite composition étant susceptible de sécher en formant, sur les dents sur lesquelles elle est appliquée, un revêtement solide transparent, translucide ou ayant la couleur des dents et de libérer ledit agent microbien en une période de temps durable au contact de sites infectés sur lesdites dents.
 - 10 2. Composition selon la revendication 1, dans laquelle le véhicule liquide est l'éthanol.
 3. Composition selon la revendication 1, dans laquelle le rapport de la benzoïne à l'agent antimicrobien acceptable par voie orale se situe approximativement dans la gamme de 10:1 à 1:10.
 - 15 4. Composition selon la revendication 1, contenant plusieurs agents antimicrobiens acceptables par voie orale.
 5. Composition selon la revendication 4, dans laquelle l'agent antimicrobien est choisi parmi l'érythromcyine, la chlorhexidine, des sels de celles-ci et des mélanges de celles-ci.
 - 20 6. Composition selon la revendication 5, dans laquelle l'agent antimicrobien est l'acétate de chlorhexidine.

25

30

35

40

45

50

55

60

65

EP 0 128 655 B1




Figure 1

EP 0 128 655 B1




Figure 2

EP 0 128 655 B1




Figure 3